"Colitis is a frequent and severe adverse event in patients treated with antibodies targeting the checkpoint inhibitor cytotoxic T-lymphocyte protein 4 (CTLA-4), but the underlying mechanisms leading to this reaction remain unclear."

#Immunology #Immunotherapy

https://www.science.org/doi/10.1126/science.adh8342